A Clinical Trial of Accelerated Dual-site Continuous Theta Burst Stimulation for Obsessive-Compulsive Disorder

Efficacy and Safety of Accelerated Sequential Dual-site Continuous Theta Burst Stimulation in Obsessive Compulsive Disorder and Neurobiological Correlates of Treatment Response: A Randomised Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105340

Enrollment

Registered

2026-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Accelerated cTBS: Continuous theta burst stimulation (cTBS) over Right dorsolateral prefrontal cortex followed by bilateral SMA at 80% active motor threshold, 1800 pulses per session ov

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age Range between 18 to 60 years. 2.Diagnosis of Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria. 3.Moderate to severe OCD, indicated by a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of more than 20. 4.Inadequate response to at least one adequate trial of a selective serotonin reuptake inhibitor (SSRI) and/or structured Cognitive Behavioral Therapy (CBT) 5.Ability to understand and sign informed consent documents.

Exclusion criteria

Exclusion criteria: 1.Current diagnosis of schizophrenia, bipolar disorder, or primary major depressive disorder. 2.Substance use disorder within the past 6 months (excluding caffeine or nicotine). 3.Any major neurological disorder (e.g., epilepsy, Parkinson s disease, or history of significant head trauma). 4.Any serious or unstable medical condition that might interfere with participation. 5.Currently pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
The change in the YBOCS score will be the primary outcome, and those with more than 35% decrease in YBOCS score will be defined as treatment respondersTimepoint: Baseline (T0), End of Treatment (T1), 4-week follow-up (T2), 12-week follow-up (T3)	—

Secondary

Measure	Time frame
Change in severity of illness and depression as measured by CGI-S, BDI, and CSSRS, respectively.Timepoint: Baseline (T0), End of Treatment (T1), 4-week follow-up (T2), 12-week follow-up (T3);To understand the neurophysiological Correlates of Treatment response in OCD using FNIRS and EEG Timepoint: Baseline (T0) and 12-week follow-up (T3)	—

Countries

India

Contacts

Public ContactGodi Sangha Mitra

AIIMS Mangalagiri

mitratriam@gmail.com09492414295

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026